Growth hormone (GH) releasing hexapeptide (GHRP)-6 and other peptidergic and non-peptidergic compounds collectively designated GH secretagogues (GHS) are potent releasers of GH in man. Their clinical future may be envisioned in three areas: therapy of GH-deficient (GHD) states, diagnosis of GHD, and non-endocrinological actions. As therapeutic agents and compared with GH itself, GHS have the disadvantage of lower potency but have a more physiological and safer profile of GH secretion. GHS administration could be indicated for states in which medium GH doses have been shown to be effective. As a diagnostic tool, the combined administration of GH releasing hormone plus GHRP-6, both at saturating doses, is currently the most powerful releaser of GH, devoid of side effects and convenient for the patient; it may also be an alternative to the insulin tolerance test for the diagnosis of GHD in adult patients. Their potential action at cardiovascular level is highly promising. Although the clinical future of GH releasing substances is appealing, probably the most relevant contribution has yet to be discovered. Once the endogenous ligand of the GHS receptor is identified, we will have an insight into the real hypothalamic control of GH secretion in man. With this knowledge it is likely that some diagnostic and therapeutic actions that are commonly undertaken will significantly change.

Keywords:
Growth hormone secretagogues, Growth hormone releasing peptide-6, Growth hormone, therapeutic, diagnostic
1.
Bowers CY, Sartor AA, Reynolds DG, Badger TAM: On the actions of the growth hormone-releasing hexapeptide, GHRP-6. Endocrinology 1991;128:2027–2035.
2.
Brosnan-Cook M, Weibel H, O’Connell M, Ynddal L, Sutter D, Green P, Nordholm L, Down J: Iontophoretic delivery of ipamorelin, a growth hormone secretagogue (abstract); in Proceedings of the 80th Annual Meeting of the Endocrine Society, New Orleans, USA, 1998, p 1/186.
3.
Carpino PA, Lefker BA, Toler SM, Pan LC, Cook ER, DiBrino JN, Hada WA, Inthavongsay J, Mangano FM, Mullins MA, Nickerson DF, Ragan JA, Rose CR, Tess DA, Wright AS, Zawistoski MP, Pirie CM, Chidsey-Frink K, Ng OC, MacLean DB, Pettersen JC, DaSilva-Jardine P, Thompson DD: Discovery of the novel pyrazolidinone-piperidine GH secretagogue (abstract); in Proceedings of the 80th Annual Meeting of the Endocrine Society, New Orleans, USA, 1998, p 2/191.
4.
Rasmussen MH, Sogaard B, Ynddal L, Groes L, Helmgaard L, Nordholm L: Ipamorelin – a very potent novel growth hormone secretagogue (abstract); in Proceedings of the 80th Annual Meeting of the Endocrine Society, New Orleans, USA, 1998, p 1/185.
5.
Casanueva FF, Dieguez C: Growth hormone secretagogues: Physiological role and clinical utility. Trends Endocrinol Metab 1999;1:30–38.
6.
Korbonits M, Grossman A: Growth hormone-releasing peptide and its analogues: novel stimuli to growth hormone release. Trends Endocrinol Metab 1995;6:43–49.
7.
Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Díaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LHT: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974–977.
8.
Ghigo E, Arvat E, Muccioli G, Camanni F: Growth hormone-releasing peptides. Eur J Endocrinol 1997;136:445–460.
9.
Peñalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C: Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine or hypoglycemia on GHRP-6-induced GH secretion in man. J Clin Endocrinol Metab 1993;76:168–171.
10.
Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E: Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 1995;61:51–56.
11.
Bowers CY, Reynolds DG, Durham D, Barrera CM, Pezzoli SS, Thorner MO: Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990;70:975–982.
12.
Popovic V, Damjanovic, Micic D, Djurovic M, Dieguez C, Casanueva FF: Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942–947.
13.
Pombo M, Barreiro J, Peñalva A, Peino R, Dieguez C, Casanueva FF: Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J Clin Endocrinol Metab 1995;80:3180–3184.
14.
Smith RG, Van der Ploeg LHT, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ Jr, Fisher MH, Nargund RP, Patchett AA: Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997;18:621–645.
15.
Micic D, Popovic V, Doknic M, Macut D, Dieguez C, Casanueva FF: Preserved growth hormone (GH) secretion in aged and very old subjects after testing with the combined stimulus GH-releasing hormone plus GH-releasing hexapeptide-6. J Clin Endocrinol Metab 1998;83:2569–2572.
16.
Dieguez C, Casanueva FF: Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol Metab 1995;6:55–59.
17.
Cordido F, Peñalva A, Dieguez C, Casanueva FF: Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 1993;76:819–823.
18.
Ramos-Díaz JC, Pimentel-Filho F, Reis AF, Lengyel AMJ: Different growth hormone (GH) responses to GH-releasing peptide and GH-releasing hormone in hyperthyroidism. J Clin Endocrinol Metab 1996;81:1343–1346.
19.
Loche S, Colao A, Cappa M, Bellone J, Aimaretti G, Farello G, Faedda A, Lombardi G, Deghenghi R, Ghigo E: The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids. J Clin Endocrinol Metab 1997;82:861–864.
20.
Giustina A, Bussi AR, Deghenghi R, Imbimbo B, Licini M, Poiesi C, Wehrenberg WB: Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. J Endocrinol 1995;146:227–232.
21.
Cuneo RC, Salomon F, McGauley GA, Sönksen PH: The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1989;37:387–397.
22.
Jørgensen JOL, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebæk NE, Christiansen JS: Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;i:1221–1224.
23.
Pombo M, Barreiro J, Peñalva A, Mallo F, Casanueva FF, Dieguez C: Plasma growth hormone response to growth hormone-releasing hexapeptide (GHRP-6) in children with short stature. Acta Pædiatr 1995;84:904–908.
24.
Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A: Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol 1995;43:631–635.
25.
Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY, Merrian GR: Effects of eight months’ treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab 1998;83:2355–2360.
26.
Pihoker C, Kearns GL, French D, Bowers CY: Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab 1998;83:1168–72.
27.
Leal A, Garcia E, Astorga R, Casanueva FF, Dieguez C: Growth hormone (GH) responses to the combined administration of GHRH plus GH-releasing peptide 6 in adults with GH deficiency. Eur J Endocrinol 1995;132:712–715.
28.
Aloi JA, Gertz BJ, Hartman ML, Huhn WC, Pezzoli SS, Wittreich JM, Krupa DA, Thorner MO: Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab 1994;79:943–949.
29.
Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO: Stimulation of the growth hormone (GH)-insulin like growth factor I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J Clin Endocrinol Metab 1996;81:4249–4257.
30.
Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR: MK-0677 an orally active growth hormone secretagogue reverses diet-induced catabolism. J Clin Endocrinol Metab 1998;83:320–325.
31.
Kirk SE, Gertz BJ, Schneider SH, Hartman ML, Pezzoli SS, Wittreich JM, Krupa DA, Seibold JR, Thorner MO: Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men. J Clin Endocrinol Metab 1997;82:1154–1159.
32.
Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Bosæus I, Sjöström L, Bengtsson B-Å: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-0677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998;83:362–369.
33.
Muccioli G, Ghè C, Papotti M, Boghen MF, Nilsson M, Deghenghi R, Ong H, Ghigo E: Tissue distribution of GHRP receptors in humans (abstract OR15-7); in Proceedings of the 6th European Congress of Endocrinology, Seville, Spain, 1998.
34.
Van den Berghe G, De Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest CH, Van Der Vorst E, Lauwers P, Bouillon R, Bowers CY: Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998;83:309–319.
© 1999 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.